Pembrolizumab in Combination with Binimetinib in Patients with Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer
Pembrolizumab and binimetinib at 30 mg are safe with manageable toxicities. Promising activity was observed in patients without liver metastases. Future larger clinical trials are warranted to further evaluate the efficacy of this chemotherapy-free combination.
Authors
- Daniel L. Adams (ORCID: https://orcid.org/0000-0002-1916-9637)
- Pooja Prem Advani (ORCID: https://orcid.org/0009-0007-5470-3149)
- E. Aubrey Thompson (ORCID: https://orcid.org/0000-0002-9001-4240)
- Alvaro Moreno‐Aspitia (ORCID: https://orcid.org/0000-0002-2317-2580)
- Keith L. Knutson (ORCID: https://orcid.org/0000-0001-9932-4467)
- Kostandinos Sideras (ORCID: https://orcid.org/0000-0002-4698-2105)
- Saranya Chumsri (ORCID: https://orcid.org/0000-0001-7117-1446)
- Dana Haley
- Edith A. Perez (ORCID: https://orcid.org/0000-0002-5037-6677)
- Joseph J. Larson (ORCID: https://orcid.org/0000-0001-8372-0465)
- Morgan Weidner
- E Liu
- Kathleen Tenner (ORCID: https://orcid.org/0000-0003-4607-4286)
- Amanda N. Arnold
Institutions
- Jacksonville College (US)
- WinnMed (US)
- Creatv MicroTech (United States) (US)
- Mayo Clinic in Arizona (US)
- Mayo Clinic in Florida (US)
Publication Details
- Journal
- Clinical Cancer Research
- Published
- 2025-03-07
- DOI
- https://doi.org/10.1158/1078-0432.ccr-24-3001
- Citations
- 3
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 3.14